author-photo

Donna L. Howe

University of Warwick

2

Papers

49

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (49)
Measurement methods for eliciting opinions on treatment benefits, toxicities and acceptable trade-offs of the two, within the PERSEPHONE trial

2017 Trials
Show All
- Source
- Cite
- Save
Citations (0)